Company: MBIO
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001410578-25-000028
Chunk: 92

Company: MUSTANG BIO, INC.
Filing Date: 2025-01-15
Form: S-1
Chunk 92
---
 and settlement of outstanding restricted stock units as of September 30, 2024; |

| ● | 60,957,004 shares of our common stock issuable upon the exercise of outstanding warrants as of September 30, 2024, with a weighted-average exercise price of $0.29 per share; |

| ● | 56,359 shares of our common stock issuable upon conversion of the Class A Common Stock, at the holders’ election; |

| ● | 16,666 shares of our common stock issuable upon conversion of the Class A Preferred Stock, at the holders’ election; |

| ● | 398,317 shares of our common stock reserved for future issuance under the 2016 Plan, plus any future increases in the number of shares of common stock reserved for issuance thereunder; and |

| ● | 338,315 shares of our common stock reserved for future issuance under the ESPP, plus any future increases, including annual automatic evergreen increases, in the number of shares of common stock reserved for issuance thereunder. |

61

DILUTION If you invest in our common stock, your interest will be immediately diluted to the extent of the difference between the public offering price per share and the as adjusted net tangible book value per share of our common stock after this offering. Net tangible book value per share represents our total tangible assets less total liabilities, divided by the number of shares of our common stock outstanding. As of September 30, 2024, our net tangible book deficit was $(8.7) million, or $(0.24) per share of common stock, based on 36,827,671 shares of common stock outstanding as of September 30, 2024. After giving effect to the sale of up to shares of common stock, pre-funded warrants to purchase up to shares of common stock, Series C-1 Warrants to purchase up to shares of common stock, Series C-2 Warrants to purchase up to shares of common stock, and Series C-3 Warrants to purchase up to shares of common stock at a public offering price per share of common stock and accompanying Warrants of $ assuming exercise in full of any pre-funded warrants offered in this offering, and after deducting the estimated placement agent fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the Warrants issued in this offering, our as adjusted net tangible book value as of September 30, 2024 would have been approximately $ million,